C9orf72-related ALS-FTD

C9orf72related ALS / FTD

[nucleotide expansion study]

TOURNAROUND TIME: 6 WEEKS

This hexanucleotide (GGGGCC) repeat expansion in the non-coding region of the C9orf72 gene is responsible for autosomal dominant amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD) (Renton et al., 2011, and DeJesus-Hernandez et al., 2011). Alleles up to 25 repeats are generally considered normal and those greater than 60 pathogenic.

Globally, this variant represents the most frequent cause of sporadic and familial ALS (7 and 38% of cases, respectively), the most frequent cause of sporadic FTD (6% of cases), and one of the most frequent causes of familial FTD (25% of cases) (Majounie et al., 2012). In Spain, this variant is responsible for 27% of familial ALS, 3% of sporadic ALS, 30% of familial FTD, and 22.58% of sporadic FTD (García-Redondo et al., 2013; van der Zee et al., 2013). Carriers of this expansion are typically diagnosed with ALS, FTD, or both diseases. Some carriers never develop the disease, which is consistent with incomplete penetrance. The initial manifestations can be pure ALS or FTD, and the appearance of other symptoms is normal throughout the course of the disease. Although there are no definitive clinical features that allow these patients to be distinguished from other ALS or FTD mutation carriers, this variant is usually associated with an earlier age at onset (regardless of initial symptoms), faster clinical course, shorter survival, bulbar onset (in case of ALS), a higher incidence of neurodegenerative diseases in relatives (mainly dementia, in 35% of cases), parkinsonism (mainly of the akinetic-rigid type with focal dystonia and poor response to levodopa), and a greater tendency to develop psychiatric symptoms such as psychosis, early-onset delusions, paranoia, and late-onset hallucinations.

REFERENCES
  1. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011 Oct 20;72(2):245-56
    https://www.ncbi.nlm.nih.gov/pubmed/21944778
  2. García-Redondo A, Dols-Icardo O, Rojas-García R, Esteban-Pérez J, Cordero-Vázquez P, Muñoz-Blanco JL, et al. Analysis of the C9orf72 gene in patients with amyotrophic lateral sclerosis in Spain and different populations worldwide. Hum Mutat. 2013 Jan;34(1):79-82
    https://www.ncbi.nlm.nih.gov/pubmed/22936364
  3. Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012 Apr;11(4):323-30
    https://www.ncbi.nlm.nih.gov/pubmed/22406228
  4. Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011 Oct 20;72(2):257-68
    https://www.ncbi.nlm.nih.gov/pubmed/21944779
  5. Van der Zee J, Gijselinck I, Dillen L, Van Langenhove T, Theuns J, Engelborghs S, et al. A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum Mutat. 2013 Feb;34(2):363-73
    https://www.ncbi.nlm.nih.gov/pubmed/23111906

 

NEUROLOGY PORTFOLIO


STUDY REQUEST
Select the panel you wish to request


INFORMED CONSENT
Required document in order to perform the study


VARIANT CLASSIFICATION
Variant classification and clinical usefulness criteria

This website uses cookies for the best user experience. If you continue browsing you are giving your consent for the acceptance of the aforementioned cookies and acceptance of our cookies policy, click on the link for more information

The cookie settings of this website are configured to "allow cookies" and thus offer you the best possible browsing experience. If you continue using this website without changing your cookie settings or clicking "Accept" you will be giving your consent to this.

Close